Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | JZMed Reports | China Pharma Outsourcing Market By 2015

China Pharma Outsourcing Market By 2015

It has been widely accepted that China is now the primary choice of outsourcing destination for drug companies around the world. In the past eight years Chinese pharmaceutical outsourcing industry has grown in an average annual rate of 48%. Starting with chemistry service only, a complete industrial structure with all service elements starts shaping. The industry's growth is also accelerated by the influx of a large number of multinational service providers whose entrance greatly up-lifted the service capability of this Chinese industry. In addition, increasing numbers of traditional Chinese pharmaceutical companies and R&D-oriented Chinese biotechnology companies also join in the service. At present, about 250 professional service providers, 50 multinational service providers, 150 traditional Chinese pharmaceutical companies and 20 Chinese biotechnology companies have formed a joint force in today's China outsourcing industry. Together, they are serving an ever enlarging body of outsourcing companies from all over the world. The industry has thus realized the service revenue of more than $1.4 B.

Nearly a decade development has significantly uplifted the industry and competition as well. How this Chinese industry would likely develop in the future has become a common concern to many professionals in all related industries. The current financial crisis also puts the future development of this industry into an uncertain path.

Would you like to know how the financial crisis affects this Chinese industry in both near term and long term? What will the industry look like in five to ten years? What are the driving forces that keep this industry still fast growing? Will China still have cost effective advantage in five to ten years? How does labor cost likely grow in next few years? How to compare it with that in other countries?

"China Pharma Outsourcing Market By 2105" is designed to address these issues and to answer these questions. It is by far the most comprehensive report about Chinese pharma outsourcing industry and market. It investigated in depth the development pattern of service capability and market size of this Chinese industry and first time displayed to the world a complete picture of China pharma outsourcing industry. In addition, with in-depth analysis of more than 50 case studies, the report also first time revealed how drug companies around the world conduct outsourcing in China and what outsourcing models are popularly pursued. More importantly, the report examined in depth both the drivers and resistors of future development of this Chinese industry. It is also the first that a clear picture of future growth and development of this Chinese industry is depicted.

The report is a must-read book to all professionals in the industries of pharmaceutical, biotechnology, financial investment and outsourcing service that are interested in pharma outsourcing in China. It is also a valuable reference book to drug regulatory agencies and other government agencies involved in strategic planning of development of pharmaceutical industry in their own countries.

Main Features of the Report

" The report started with examining in depth the current market size, industry structural composition and service capability in each sector of this Chinese industry. A clear and complete picture of current development state of China pharma outsourcing industry is thus first time displayed to the world.

" The report then studied in detail how China's labor cost, one of the key attractions to all outsourcing companies, climbed in past few years. Based on this development trend, it is also the first time that the report provided a clear picture of how China's cost effective advantage would likely develop in following 5-7 years and how this development could be compared with the same criteria in other countries during the same time period. It therefore gives a clear idea why it is still cost effective to conduct outsourcing in China in next few years and by when China's this advantage would likely completely disappear.

" The report examined in-depth more than 50 outsourcing case studies. It illustrated in detail how drug companies from all over the world, large, small and even startup, are conducting outsourcing in China. It is thus also the first time that the report revealed the most popular China outsourcing models pursued by all sized drug companies.

" The report analyzed in depth how pharma/biotech companies, large or small, will cope with the financial crisis. Based on the analysis, the report first time pointed out how China outsourcing in general and each service sector in specific would likely be affected.

" The report further analyzed in depth all drivers and resistors for future development of this Chinese industry. The report discovered that there are three outsourcing waves that will successively drive the growth of this Chinese industry. Based on these analysis results, the report also first time depicted a clear picture of future growth and development in both short term and long term of this Chinese industry.

" The report contains the most complete data in numerous aspects about China and the Chinese industries of pharmaceutical, biotechnology and outsourcing. In addition, it also contains in-depth analysis on the quality of Chinese technical workforce in pharmaceutical industry.

" What is more useful to all companies is that the report contains the most complete, up-to-date information of both service capability and contact information of 46 best Chinese professional service providers, 50 China-based multinational service providers, 22 best traditional Chinese pharmaceutical companies and 15 R&D-focused Chinese biotech companies that are involved in outsourcing service.

Your Questions Are Answered

The report addressed each of the following questions most concerned by professionals in a variety of industries:

" What is the current market size of the China pharma outsourcing industry? What is the market size of each service sector?

" What is the best outsourcing model at present? Who are in China? What outsourcing activities are most drug companies conducting in China?

" Whether my company should have a China strategy? What strategies should I have?

" How does the current financial crisis affect China's pharma outsourcing industry? What is the near term and long term effects of the crisis on the growth of this Chinese industry? Which service sector(s) would be hit harder than others? How to compare the effect of the crisis on this Chinese industry with the same industry in other countries?

" Why does China still have advantages in outsourcing over other countries? Will China still have cost effective advantage in five to ten years? How does labor cost likely grow in next few years? How to compare it with that in other countries?

" What is the current structure of each service sector of the industry? What is the current service capability of each sector? What are current issues the industry needs to resolve?

" What are the drivers that will drive future growth of this Chinese industry? Which service sector has been growing fastest so far? Which sector will have most future growth potential?

" What will the industry look like in five to ten years? What about the market size by then? How will the service capability of this industry develop in the future?

" How will global pharma outsourcing industry develop in the future? What roles will this Chinese industry play?

Benefits the Report Will Bring You

" The report makes you quickly understand the current development state of China pharma outsourcing industry including its current market size and its position in world pharma outsourcing industry.

" The report helps you gain a clear picture of whether, why and how this Chinese industry will further develop in the future.

" The report makes you quickly gain detailed insights of why all types of drug companies go to China for outsourcing and what outsourcing models most suitable to your company.

" The report helps you figure out whether your company should have a China strategy incorporated into your company's long term development goals.

" The report gives you a detailed picture of what service is currently available in China and their capability level. It helps you decide whether it is the right time to outsource your specific projects to China.

" The report further helps you figure out which China-based service provider most fits your outsourcing criteria and how to approach them.

" The report also provides you with a detailed analysis of how labor cost would likely develop in China. It greatly helps you decide why you should take China's this advantage as early as possible if cost effectiveness is one of your main concerns.

" The report helps you gain a complete insight into the development state of global pharmaceutical outsourcing industry.

Jim J. Zhang, Ph. D.

Jim J. Zhang currently is president and managing director of JZMed, Inc., a US-based, full scale pharmaceutical service company specializing in outsourcing to China. Before founding the company, Jim worked for nine years with Albany Molecular Research, Inc. (AMRI), a US-based and currently one of the world largest CROs. During his tenure at AMRI Jim was responsible for managing and overseeing multiple drug R&D projects that involved the international cooperation of AMRI's multiple sites (USA, Singapore and Hungary). He played key roles in helping numerous pharma and biotech companies discover and develop a series of drug candidates that later entered preclinical and clinical development including advanced clinical trials. He was also the key contributor to the development of chemical production process for several developmental drugs. Prior to pursuing his Ph.D. program in the US, Jim worked for six years in a China-based CMO as process engineer and developed production process for a number of pharma products.

In the practice of more than fifteen years Jim developed his expertise in chemical process research and development and in the therapeutic areas of viral infection, cancer, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Currently he holds 18 patents and is also the principal author of 11 peer-reviewed research articles.

Jim received his master's degree in Chemical Engineering from East China University of Science & Technology (Shanghai), and his Ph.D. degree in Synthetic Organic Chemistry from the University of Iowa. He also received additional trainings in Medicinal Chemistry through working at Research Triangle Institute (Research Triangle Park, North Carolina).

January 2009 PDF
Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions